IP Library Granted Patent US 6,986,881
Granted Patent B1
US 6,986,881 · App. 10/009,584 · Granted Jan 17, 2006

Identification of compounds that modify transcriptional responses to hypoxia

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,986,881
App. No.
10/009,584
Granted
Jan 17, 2006
Kind
B1
Abstract

The invention provides methods for identifying compounds that can be used to modify transcriptional responses to hypoxia, and use of such compounds in therapeutic and diagnostic methods.

Claims (11)

1. An in vivo method of identifying a compound that modulates a transcriptional response to hypoxia, said method comprising:

contacting a cell in vivo, or the extracellular environment of a cell in vivo, with a candidate compound;

subjecting the cell in vivo to hypoxic conditions; and

assessing a transcriptional response of the cell to the hypoxic conditions, wherein an increase or decrease in the transcriptional response to hypoxia in the cell in the presence of the candidate compound compared to the transcriptional response to hypoxia in a cell in the absence of the candidate compound indicates that the candidate compound modulates the transcriptional response to hypoxia.

2. The method of claim 1 , wherein the transcriptional response is expression of a reporter gene under the control of a hypoxia-responsive promoter or an endogenous hypoxia-responsive gene.

3. The method of claim 1 , wherein the cell is in a mammal.

4. The method of claim 1 , wherein the hypoxic conditions to which the cells are exposed are induced by deferoxamine or cobalt chloride.

5. The method of claim 1 , wherein said candidate compound is a peptide.

6. The method of claim 1 , wherein said candidate compound is a small molecule.

7. The method of claim 2 , wherein the reporter gene encodes luciferase, green fluorescent protein, yellow fluorescent protein, or cyano-fluorescent protein.

8. The method of claim 2 , wherein the endogenous gene encodes vascular endothelial growth factor, erythropoietin, heme oxygenase, inducible nitric oxide synthase (iNOS), glucose transporter 1, glucose transporter 3, hexokinase, aldolase A (ALDA), or transferrin.

Assignments (4)
CONFIRMATORY LICENSE Recorded Aug 8, 2016
From: DANA-FARBER CANCER INST
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039601/0599 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 31, 2005
From: SEMICONDUCTOR COMPONENTS INDUSTRIES, LLC
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 016183/0001 →
RE-RECORD TO CORRECT THE NAME AND ADDRESS OF THE ASSIGNEE, PREVIOUSLY RECORDED ON REEL 012910 FRAME 0064, ASSIGNOR CONFIRMS THE ASSIGNMENT OF THE ENTIRE INTEREST. Recorded Oct 7, 2002
From: LIVINGSTON, DAVID M.; KUNG, ANDREW L.; BHATTACHARYA, SHOUMO
To: DANA FARBER CANCER INSTITUTE, INC.
Reel/Frame 013367/0204 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 15, 2002
From: LIVINGSTON, DAVID M.; KUNG, ANDREW L.; BHATTACHARYA, SHOUMO
To: CURAGEN CORPORATION
Reel/Frame 012910/0064 →